Retinal disease therapy
Multi-pronged attack on underlying retinal disease processes drives current research
Leigh Spielberg
Published: Wednesday, March 1, 2017
Cell therapy refers to the transplantation of either HLA-typed RPE cells or stem cells, or a more pharmacologic approach to the diseased cells.GENE THERAPY Gene therapy focuses on treatment of early-stage disease. Because these diseases are monogenetic, they are ideal candidates for gene therapy. The goals include replacing or knocking down a defective gene, controlling gene expression, delivering a suppressor or correcting a mutation that misdirects splicing. With 204 causative genes identified and 244 retinal dystrophy loci mapped, there is clearly no shortage of targets. “Ongoing and anticipated gene therapy trials include treatments for Leber’s congenital amaurosis (LCA) Type 2, choroideremia, Leber’s hereditary optic neuropathy (LHON), Stargardt and Usher syndrome Type 1B,” said Dr Richard. RETINAL IMPLANTS Dr Richard then turned his attention to retinal implant (prosthetic) technology. This incorporates two primary external components: a camera chip and a retina encoder; and an implanted component: the retinal stimulator, which receives pulse sequences and transmits them to the retina. “Visual improvement by retinal stimulation is definitely possible. However, high-resolution implants are difficult to achieve,” said Dr Richard. This was evident in the five-year trial of the Argus II implant, in which patients were clearly able to recognise and use shapes for orientation and environmental information, but do not have any fine resolution. This is because the current maximum number of electrodes per square millimetre is 37. Each electrode generates one phosphene. However, to obtain normal reading speed, more than 5,000 phosphenes are needed per square millimetre. Dr Richard remains very optimistic. “Who knows what the future holds?” Gisbert Richard: richard@uke.de
Tags: Artificial vision, stem cell therapy
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular
Long-awaited cellular therapies for corneal endothelial disease enter the clinic.
Balancing Innovation and Safety
Ensuring access to advanced cell therapies amid regulatory overhaul.
With Eyes on Its Future, ESCRS Celebrates Its Past
Winter Meeting offers opportunities to experiment with new concepts and formats.
Best of ESCRS Winter Meeting 2024
Following the New Generation
EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.
Refocus on Multifocals
Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.
Common Myths in Presbyopia Correction
Patient education key to satisfaction with refractive IOLs.
Reversible Multifocality
Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.
Managing a Cataract Surgery Refractive Miss
Weighing the pros and cons of options for intraocular intervention.
Unleashing OCT’s Full Potential
Performance of newest tool for corneal evaluation meets or beats older standard technologies.